Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
tiopental life medical 0.5 g
life medical aps (1) - tiopentalnatrium - pulver til injeksjonsvæske, oppløsning - 0.5 g
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
tiopental life medical 1 g
life medical aps (1) - tiopentalnatrium - pulver til injeksjonsvæske, oppløsning - 1 g
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
toradol 30 mg/ ml
atnahs pharma netherlands b.v. - ketorolaktrometamol - injeksjonsvæske, oppløsning - 30 mg/ ml
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
toradol 30 mg/ ml
2care4 aps - ketorolaktrometamol - injeksjonsvæske, oppløsning - 30 mg/ ml
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
vallergan 5 mg/ ml
sanofi-aventis norge (3) - alimemazinhemitartrat - mikstur, oppløsning - 5 mg/ ml
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
vallergan 10 mg
sanofi-aventis norge (3) - alimemazinhemitartrat - tablett, filmdrasjert - 10 mg
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
hypotron 5 mg
brancaster pharma ireland ltd. - midodrinhydroklorid - tablett - 5 mg
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
hypotron 2.5 mg
brancaster pharma ireland ltd. - midodrinhydroklorid - tablett - 2.5 mg
Νορβηγία -
Νορβηγικά -
Statens legemiddelverk
uvadex 20 mikrog/ ml
therakos europe ltd - metoksalen - oppløsning til blodfraksjonsmodifisering - 20 mikrog/ ml
Ευρωπαϊκή Ένωση -
Νορβηγικά -
EMA (European Medicines Agency)
sarclisa
sanofi winthrop industrie - isatuximab - multippelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.